



August 4, 2020

BSE Limited,
Department of Corporate Services,
P. J. Towers, Dalal Street,
Mumbai Samachar Marg,
MUMBAI - 400 001.

✓ **National Stock Exchange of India Ltd.,**
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
MUMBAI - 400 051.

Dear Sir/Madam,

**Sub: Disclosure pursuant to Regulation 30 of the SEBI
(Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Enclosed is a Press Release as regards receipt of tentative approval from the U.S. FDA for the Company's Empagliflozin Tablets, 10 mg and 25 mg, to market a generic version of Jardiance® Tablets, 10 mg and 25 mg, of Boehringer Ingelheim Pharmaceuticals, Inc.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

For LUPIN LIMITED

RAJVARDH
AN VISHNU
SATAM

Digitally signed by RAJVARDHAN
VISHNU SATAM
DN: c=IN, o=Personal,
postalCode=400062, st=Maharashtra,
2.5.4.20=c19d8d961d9f5d9e973a093a4
d55462532eb29496ea7e2abcf74700f53
79b7,
serialNumber=d8beef0a8c796663c73
8ea75564b4752195726c8dc7a2096c4
242771b2a, cn=RAJVARDHAN VISHNU
SATAM
Date: 2020.08.04 14:18:35 +05'30'

R. V. SATAM
COMPANY SECRETARY
(ACS - 11973)

Encl- : a/a.

BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPCIN

Lupin Receives Tentative Approval for Empagliflozin Tablets

Mumbai, Baltimore, August 04, 2020: Pharma major Lupin Limited (Lupin) announced that it has received tentative approval for its Empagliflozin Tablets, 10 mg and 25 mg, from the United States Food and Drug Administration (U.S. FDA) to market a generic version of Jardiance® Tablets, 10 mg and 25 mg, of Boehringer Ingelheim Pharmaceuticals, Inc.

Empagliflozin Tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Empagliflozin Tablets, 10 mg and 25 mg (RLD: Jardiance®) had an annual sales of approximately USD 4,368 million in the U.S. (IQVIA MAT Mar 2020).

About Lupin

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.

The Company enjoys leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women's health areas. Lupin is the third largest pharmaceutical company in the U.S. by prescriptions and in India by global revenues. The Company invests 9.6 % of its revenues on research and development.

Lupin has fifteen manufacturing sites, seven research centers, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.

Please visit www.lupin.com for more information.

Follow us on Twitter: www.twitter.com/LupinGlobal | LinkedIn: www.linkedin.com/company/lupin/

Facebook: www.facebook.com/LupinWorld/

For further information or queries please contact –

Arvind Bothra

Head – Investor Relations and Corporate Communications

Email: arvindbothra@lupin.com

Tel: +91 22 6640 8237

Manjira Sharma

General Manager – Corporate Communications

Email: manjirasharma@lupin.com

Tel: +91 22 6640 2532

*Safe Harbor Statement

Jardiance® is a registered trademark of Boehringer Ingelheim International GmbH